Dabur India Limited — PPTs, 07-05-2025: Investor Presentation

1. Financial Highlights:

Dabur posted consolidated revenue of INR 12,563 Cr for FY25, up 1.3% YoY, with growth constrained by inventory correction and partner ROI support. Operating profit dipped 3.5% to INR 2,316 Cr, dragging margins down to 18.4% from 19.4%. PAT declined 4.1% to INR 1,768 Cr. International sales rose 7.7% in INR terms (17.2% in constant currency), accounting for about 26% of overall sales. Domestic FMCG was driven by Foods & Beverages (49.7%), Health Care (31.3%), and Home & Personal Care (17%). Q4 revenue was INR 2,830 Cr (+0.6% YoY), while PAT dropped 8.4% to INR 320 Cr. Standalone revenue remained flat at INR 9,071 Cr; net profit fell 7% to INR 1,403 Cr.

2. Strategic Initiatives & Growth Drivers:

Focus on premiumization and portfolio refresh, targeting health & wellness categories, is accelerating profitable growth. The GTM 2.0 strategy prioritizes distributor consolidation, channel expansion, and cost management. Dabur is rationalizing underperforming SKUs to allocate capital to core brands and strategic M&A in new-age healthcare and wellness foods. Enhanced brand campaigns—like Dabur Honey for weight management and Meswak—support demand. Digitization and capex investments aim to improve operational efficiency.

3. Business Developments:

Q4 growth stemmed from Foods (14.2%) and Health supplements (+10%). Real juice expanded its premium segment, and Badshah volumes grew 11%, benefiting from new market entries in Rajasthan and Madhya Pradesh. Hair oils and Homecare gained market share with mid to high single-digit growth. New product launches and marketing initiatives strengthened Ayurvedic oral care and wellness segments.

4. Market Position & Competitive Advantage:

Dabur maintains leadership in Ayurveda-based healthcare and natural FMCG with trusted, differentiated brands like Hajmola, Real juice, and Meswak showing steady market share gains. Its broad portfolio and scale provide resilience amid volume softness and competition. Robust international growth (17.2% CC) highlights strong presence in MENA, Egypt, and Turkey, supporting geographic diversification.

5. Investor Implications:

The strategic pivot toward premium and wellness categories underpins positive growth potential despite short-term margin pressure. Execution risks lie in GTM transformation and portfolio rationalization. International expansion adds upside. Investors should monitor volume trends and cost efficiencies as critical factors. A stable dividend payout (~800%) reflects strong cash flow generation and shareholder returns.